5p15/ 9q22/ 15q22 Hyperdiploidy and Their Significance in Multiple Myeloma Patients

NCT06667583 | Not Yet Recruiting

• 1 other identifier: Hyperdiploidy in MM Patients
• Study Type: observational
• Target: 40
• Locations: 0 countries
• Sites: N/A

Brief Summary

Our study aims to detect 5p15/ 9q22/ 15q22 hyperdiploidy and thier significance in Multiple Myeloma patients

Conditions

Multiple Myeloma, Neoplasms

Keywords

Hyperdiploidy

Outcome Measures

Primary Outcomes (1)

• detection of 5p15/ 9q22/ 15q22 hyperdiploidy and thier significance in Multiple Myeloma patients

  detection of 5p15/ 9q22/ 15q22 hyperdiploidy and thier significance in Multiple Myeloma patients

  up to 2 yeqrs

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Newly diagnosed Multiple Myeloma Patients

You may qualify if:

• Newly diagnosed Multiple Myeloma Patients -

You may not qualify if:

• Patient of Multiple Myeloma who received treatment

Sponsors & Collaborators

• Assiut University: lead

Related Links

• Ravi, G. and Gonsalves, W.I. (2021) Current Diagnosis, Risk Stratification and Treatment Paradigms in Newly Diagnosed Multiple Myeloma. Cancer Treatment and Research Communications, 29, Article ID: 100444
• Nassar, S., Taher, A., Spear, R., Wang, F., Madewell, J.E. and Mujtaba, B. (2021) Multiple Myeloma: Role of Imaging in Diagnosis, Staging, and Treatment Response Assessment. Seminars in Ultrasound, CT and MRI, 42, 184-193.
• Abdallah, N., et al. (2020). Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response.

Biospecimen

Retention: SAMPLES WITH DNA

Bone Marrow Aspirate

MeSH Terms

Conditions

Multiple Myeloma; Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms, Plasma Cell; Neoplasms by Histologic Type; Hemostatic Disorders; Vascular Diseases; Cardiovascular Diseases; Paraproteinemias; Blood Protein Disorders; Hematologic Diseases; Hemic and Lymphatic Diseases; Hemorrhagic Disorders; Lymphoproliferative Disorders; Immunoproliferative Disorders; Immune System Diseases

Study Officials

• dalia abd el naser, resident dr

  Assiut University

  PRINCIPAL INVESTIGATOR

• Eman Zaki, Professor

  Assiut University

  STUDY DIRECTOR

• safia hussein, Lecturer

  Assiut University

  STUDY DIRECTOR

• mohammed El nagar, Ass profesor

  Assiut University

  STUDY DIRECTOR

Central Study Contacts

Dalia Abd el naser, resident dr

CONTACT

01016321671; Dalia.16266095@med.aun.edu.eg

Safia Hussein, Lecturer

CONTACT

+20 114 393 0280; dr_safia@aun.edu.eg

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: dr dalia gamal

Study Record Dates

• First Submitted: October 29, 2024
• First Posted: October 31, 2024
• Study Start: December 1, 2024
• Primary Completion: December 1, 2025
• Study Completion: January 1, 2026
• Last Updated: November 1, 2024

Record last verified: 2024-10

Data Sharing

• IPD Sharing: Will not share